Innate and adaptive immune responses to tick-borne flavivirus infection in sheep by Mansfield, Karen L et al.
Innate and adaptive immune responses to tick-borne flavivirus infection in sheep

Karen L Mansfield a,b,#, Nicholas Johnson a, Ashley C Banyard a, Alejandro Núñez c, Matthew Baylis d,e, Tom Solomon b,e,f,*, Anthony R Fooks a,e,g,*

aWildlife Zoonoses and Vector-borne Diseases Research Group, Animal and Plant Health Agency (APHA), Woodham Lane, New Haw, Surrey, KT15 3NB, UK
bBrain Infections Group, Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 7BE, UK
cPathology Department, Animal and Plant Health Agency (APHA), Woodham Lane, New Haw, Addlestone, Surrey, KT15 3NB, UK
dDepartment of Epidemiology and Population Health, Institute of Infection and Global Health, University of Liverpool, Liverpool, CH64 7TE, UK
eNIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, L69 7BE, UK
fWalton Centre NHS Foundation Trust, Liverpool, L9 7LJ, UK
gDepartment of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, L69 7BE, UK

#corresponding author: Dr Karen Mansfield; Karen.Mansfield@apha.gsi.gov.uk (​mailto:Karen.Mansfield@apha.gsi.gov.uk​), 
*both senior authors contributed equally

Running title: immune response to tick-borne flavivirus infection in sheep


Abstract 
The flaviviruses tick-borne encephalitis virus (TBEV) and louping ill virus (LIV) are closely-related genetically and antigenically, have broadly similar host ranges that include rodents and other mammals (including sheep), and are both transmitted by the same tick species, Ixodes ricinus.  Although human infection with TBEV results in a febrile illness followed in some cases by encephalitis, humans appear to be much less susceptible to infection with LIV. However, these viruses demonstrate different susceptibilities in sheep; LIV infection causes encephalitic disease, whereas TBEV infection generally does not. To investigate the role of the immune response in this mixed outcome, groups of sheep were inoculated with either virus, or with a primary inoculation with one virus and secondary inoculation with the other. Markers of both adaptive and innate immune responses were measured. In each group studied, infection resulted in seroconversion, demonstrated by the detection of virus specific neutralising antibodies. This appeared to control infection with TBEV but not LIV, which progressed to a febrile infection, with transient viraemia and elevated levels of serum interferon. This was followed by neuroinvasion, leading to up-regulation of innate immune transcripts in discrete areas of the brain, including interferon inducible genes and chemokines. Prior inoculation with TBEV did not prevent infection with LIV, but did appear to reduce disease severity and viraemia. We postulate that LIV has adapted to replicate efficiently in sheep cells, and disseminate rapidly following infection. By contrast, TBEV fails to disseminate in sheep and is controlled by the immune response.



Introduction
	Louping ill virus (LIV) and tick-borne encephalitis virus (TBEV) are zoonotic members of the genus Flavivirus, family Flaviviridae (Calisher 1988). Both viruses are members of the tick-borne flavivirus lineage, transmitted by the tick species Ixodes ricinus (I. ricinus) in Europe (Gritsun et al., 2003). Although TBEV is not detected in the United Kingdom (UK), it is indigenous across a vast geographical area from Western Europe to Asia, where it causes many cases of human disease. Human infection with TBEV leads to fever and encephalitis, which can be fatal (Mansfield et al., 2009). Wild mammals participate in the ecological cycle of TBEV and have been shown to seroconvert (Klaus et al., 2010). However, neurological disease in wild and domestic sheep following infection with TBEV is exceedingly rare (Bago et al., 2002). 
LIV causes encephalitis in sheep, with the highest prevalence in upland areas of the UK, (Jeffries et al., 2014).  LIV has also been reported from Norway and Spain (Gao et al., 1993; Balseiro et al., 2012), and closely-related viruses have been detected in Spain, Greece and Turkey (Hartley et al., 1969; Papadopoulos et al., 1971; Gonzalez et al., 1987; Mansfield et al., 2015).  Seroprevalence studies have indicated the exposure of wildlife to LIV, but instances of disease are rare (Reid et al., 1978). Occasional cases of human disease caused by LIV have also been reported (Davidson et al., 1991).  LIV infection in sheep leads to pyrexia and viraemia, resulting in widespread dissemination of virus. Infected sheep may show a partial recovery before developing severe neurological disease symptomatic of encephalitis (Jeffries et al., 2014). An extensive series of studies into LIV infection in sheep demonstrated relationships between viraemia, neutralising antibodies and the pathology of disease in the infected brain (Doherty & Reid, 1971; Reid & Doherty, 1971). Later studies confirmed the presence of perivascular cuffing and mononuclear infiltration of the brain parenchyma (Sheahan et al., 2002). TBEV causes similar lesions in the brains of infected humans, typical of viral encephalitis (Gelpy et al., 2005), but there is no evidence to suggest that this virus can cause neuroinvasion in other mammalian species. 
	The geographical area affected by TBEV has expanded across Europe (Mansfield et al., 2009), and the incidence of LIV cases in UK sheep has also increased (Jeffries et al., 2014), prompting an investigation into the factors underlying the different outcomes of infection in ruminants.  Aside from the neutralising antibody response, little is known about the immune response to flavivirus infection in sheep. Through an in vivo model of LIV and TBEV infection, the immune response to infection in sheep was investigated, including the response to serial infection with both viruses to assess whether prior infection with one virus modifies the outcome of infection with a second. Infections with LIV and TBEV in a sheep model have dramatically different outcomes, with LIV progressing to overt neurological disease associated with extensive encephalitis, whereas TBEV infection appears to be controlled at an early stage with no evidence of virus dissemination. We also report evidence for innate immune responses to LIV infection within the central nervous system (CNS) of infected sheep. However, this does not appear to control virus spread or disease progression.

Materials and Methods
Ethics statement
	All animal work was undertaken in accordance with Home Office (UK) guidelines and legislation, and was covered by the Home Office Animals (Scientific Procedures) Act 1986, project license number PPL 70/6411.  Ethical approval was granted by the APHA Ethical Review Committee. Humane endpoints were identified prior to undertaking these experiments and euthanasia applied when these endpoints were reached.


Virus isolates
	LIV strain LI 3/1 (designated Arb 126) was originally isolated from a sheep in Oban, Scotland and TBEV strain Neudorfl (designated Arb 131) was isolated from an I. ricinus tick in Austria in the early 1950s. Both virus isolates were a kind gift from Professor John Stephenson (Public Health England, formerly Centre for Applied Microbiology and Research, Porton Down, UK).  The TBEV isolate originated from Dr Christian Kunz, University of Vienna, Austria, and was subsequently passaged four times in an outbred strain of mice.  The LIV isolate originated from Dr Hugh Reid, Moredun Institute, Scotland, and was passaged four times in sheep and six times in an outbred strain of mice. Subcutaneous inoculation of CD-1 mice with either virus resulted in neuroinvasion within 5 days (data not shown).  Both LIV strain LI3/1 and TBEV strain Neudorfl have been fully sequenced and can be obtained using GenBank Accession numbers KP144331 and U27495 respectively.

Experimental infection in sheep
	For direct comparison between viruses, two groups of Poll Dorset/Poll Dorset cross male lambs (n=5), aged approximately 6 months, were inoculated subcutaneously with 5 x 106 PFU of either LIV or TBEV, diluted in Eagle’s minimum essential medium (E-MEM).  
Additionally, two groups were inoculated in order to investigate heterologous flavivirus infection, with a lower dose of 5 x 103 PFU of LIV or TBEV administered at day 0, followed by the higher dose of 5 x 105 PFU of the heterologous virus at 11 days post-infection (DPI). 
A control group (n=3) received a subcutaneous inoculation of E-MEM.  Clinical course was monitored, and clinical signs were classified as follows:
(-): no clinical signs observed
(+): lethargic, lying down, inappetence, pyrexia, panting, spontaneous nibbling, sensitivity to noise
(++): ataxia, profuse diarrhoea, head-tremor, body-tremor, head-shaking, dis-jointed gait, circling, louping.
(+++): paralysis, convulsions
Serial blood samples were also taken every 48-72 hours, including a pre-bleed 6 days prior to inoculation.  Post-mortem tissue samples were taken for analysis.

Detection of virus particles in serum
	Virus was detected in serum samples by plaque assay on Vero C1008 cells using standard techniques, to determine titre as PFU/ml of sera.

Detection of virus by RT-PCR
	Total RNA was extracted from serum using TRIzol® LS (Invitrogen), and from tissue using TRIzol® reagent (Invitrogen).  Extracted RNA was re-suspended in nuclease-free water and treated with 0.3 units/µl DNAse using the RNeasy Mini Kit (Qiagen).  cDNA was prepared through reverse transcription with Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Promega) and 10X random hexamers (or 0.5µg Oligo dT15 primer).  Amplification was undertaken using Amplitaq Gold® DNA polymerase (Applied Biosystems), with 10pmol of sense and anti-sense primers TBEV-E F1 (5’- CCTATGAGTGTGTGACCATAG-3’) and TBEV-E R1 (5’- CAGCCTCGATCACTCTG-3’). 



Quantification of virus in CNS tissues
	Equivalent weights of tissue samples were homogenised in tissue culture medium using a Tissue Lyser II (Qiagen).  Homogenates were centrifuged for 10 minutes/14,000 rpm/4°C, and 30µl of the supernatant was titrated in Vero C1008 cells, as described above, to determine virus titre as PFU/mg tissue.

Quantification of type-1 IFN bioactivity in sheep serum
Type I interferon (IFN) was detected in sheep serum using an Mx/CAT reporter assay.  This assay used the transfected cell line MDBK-t2 which encodes the enzyme chloramphenicol acetyltransferase (CAT) when serum type-1 IFN binds to the cell.  Sub-confluent MDBK-t2 cells were seeded in 96-well plates, at 2.5 x 104 cells/well (50µl volume).  A porcine IFN-α standard curve was prepared on each plate tested, with doubling dilutions from 2500U/ml to 39.0625U/ml.  50µl of each standard was added in triplicate to each plate tested, along with a media-only negative control.  Serum samples were diluted 1/2.5 in serum-free Dulbecco’s Modified Eagle Medium (D-MEM), and 50µl was added to the plate in triplicate.  Plates were incubated for 24 hours at 37°C/5% CO2.  The cell monolayer was washed with pre-cooled Dulbecco's Phosphate-Buffered Saline (DPBS).  A commercial CAT ELISA (Roche) was then performed with lysed cell extracts, to quantitatively measure CAT expression in these cells.  A standard curve was generated (scatter graph), using the mean optical density (OD) readings for the standards from all plates, and the equation of the resulting linear relationship was determined, from which the IFN-α (U/ml) in each serum sample could be calculated.


Detection of serum neutralising antibodies
The plaque reduction neutralisation test (PRNT) was performed as previously described (Mansfield et al., 2011).

Detection of cytokine and chemokine transcripts in the brain
RNA transcript modulation was determined using previously described methods (McKimmie et al., 2005).  All transcript-specific primer pairs were designed as part of this study, and are available upon request.

Pathology and immunohistochemistry
	Post-mortem brain and spinal cord samples from thoracic and lumbar regions were fixed in 10% neutral buffered formalin (NBF) for a minimum of five days.  These were then blocked and processed routinely to paraffin wax.  Serial 4μm wax sections were cut and either stained with haematoxylin and eosin (H&E) using standard methods for structural examination, or used for immunohistochemistry.  Immunolabelling for T cells with polyclonal rabbit anti-human CD3 (Dako A0452) overnight at 4˚C, or B cells with monoclonal mouse anti-human CD79a (Dako) at 20°C for 1 hour. Protein-concentration-matched normal rabbit immunoglobulin (IgG) or normal mouse immunoglobulin (IgG) (Vector Laboratories, UK) isotype antibodies were included as technique controls.  Biotinylated secondary antibodies were incubated for 30 minutes at room temperature; goat anti-rabbit IgG (Vector Laboratories) for CD3 detection, and goat anti-mouse IgG (Vector Laboratories) for CD79a detection.  5% normal sheep serum was added to the biotinylated secondary antibody to prevent non-specific binding. This was followed by incubation with ABC elite avidin-biotin-peroxidase conjugate (Vector Laboratories) for 30 minutes. Sections were washed three times with x2 TBS between incubations. The immunohistochemical signal was visualised using 3,3 diaminobenzidine tetrahydrochloride (DAB).  Following a wash step with purified water for 5 minutes and running tap water for 5 minutes, sections were counterstained in Mayer’s Haematoxylin Counterstain (Leica Biosystems), dehydrated in absolute alcohol, cleared in xylene, and mounted using DPX mountant (VWR) and a coverslip.

Statistical analysis
	For analysis of cytokine/chemokine transcriptional data, the raw data was transformed (log [n+1]) and a One-Way ANOVA was used to determine the effect of treatment (LIV/TBEV infection), in association with Tukey’s test for comparison of means.  Transformed data were displayed graphically, with detransformed ([antilog n] -1) means for each test group detailed in the figure legend.  For all remaining data analysis involving comparison of inoculation groups, the mean of each test group within an assay was calculated, and the standard error of the mean (SEM) determined by dividing the standard deviation by the square root (√) of the number of replicates in each test group.  Statistical significance between test groups was determined by Student’s t-test (homoscedastic, two-tailed distribution).  With such small sample sizes, it is generally accepted that only a fairly large effect will be statistically significant, therefore results are displayed graphically in order to give a visual impression of the data.  A p-value of <0.05 was deemed significant, and significant changes were denoted in the figures by * (p<0.05), ** (p<0.01) or *** (p<0.001).  

Results
Infection with LIV causes clinical disease in sheep, whilst TBEV does not
Inoculation of sheep with a single dose of 5 x 105 PFU of LIV resulted in severe clinical disease characterised by suppressed appetite, diarrhoea and weight loss. The development of pyrexia commenced at 3 DPI, with body temperatures remaining significantly elevated between 4 – 8 DPI (Figure 1a). During this period sheep developed moderate to severe neurological clinical signs (Table 1), as defined in the Materials and Methods.  Three animals exhibited clinical signs which included ataxia, altered gait, unresponsiveness, opisthotonus and convulsions, and underwent euthanasia at 8 DPI.  One animal had appeared to recover, although it retained residual signs such as nibbling and altered gait until humanely killed at 14 DPI following a whole body tremor. The remaining animal in this group exhibited only spontaneous nibbling and a fine head tremor, and was humanely killed at 16 DPI following an increase in the severity of head shaking.  The significant pyrexia observed from 4 DPI was associated with detection of viraemia at 4 DPI (Table 1). Sheep with more severe clinical signs that underwent euthanasia earlier appeared to have lower levels of viraemia than sheep 91375, which exhibited less severe clinical signs and was euthanized at 14 DPI. Sheep 91389, which underwent euthanasia at 16 DPI, had no detectable viraemia despite developing clinical signs of neurological disease. 
In comparison, sheep infected with a single dose of TBEV (5 x 105 PFU) exhibited no signs of disease over the course of the experiment.  

Pre-exposure to TBEV delays the onset of LIV-induced disease
Within the heterologous inoculation groups, inoculation with a lower primary dose of 5 x 103 PFU of LIV induced a similar rectal temperature profile to that observed in the single higher dose inoculation group, but only in three animals, and with a lower increase in temperature (figure 1b). Only one of these animals had detectable viraemia between 4-7 DPI, and this animal also had detectable levels of viral RNA in the lumbar spinal cord at post-mortem. The secondary inoculation of 5 x 105 PFU of TBEV at 11 DPI had no effect on rectal temperature.  Apart from the initial pyrexia observed, other clinical signs were not detected until 16 DPI in three animals from this group, and were milder in nature (head shaking and nibbling), whilst one animal (91391) in this group did not exhibit any clinical signs throughout the experiment.
  By comparison, in the group that received the lower primary dose of 5 x 103 PFU of TBEV, no clinical signs were initially observed.  However, the secondary inoculation at 11 DPI with 5 x 105 PFU of LIV induced a steady increase in rectal temperature from 17 DPI (figure 1b), which coincided with the onset of spontaneous nibbling and hyperventilation in three animals at 18 DPI.  One of these animals was humanely killed at 19 DPI following the onset of hind-limb paralysis.  Therefore, when compared to the group inoculated with a single higher dose of LIV (figure 1a), the increase in rectal temperature associated with LIV infection was delayed by approximately 3 days, suggesting that the primary dose of TBEV had influenced the disease course of LIV infection.  

Infection with LIV stimulates the innate immune response
The increase in rectal temperature following homologous LIV inoculation also correlated with an increase in mean serum IFN-α detected over the baseline (uninfected control, 0 DPI) at 2 and 4 DPI, which was statistically significant at 4 DPI (p = 0.037) (Figure 1c).  One TBEV-infected sheep demonstrated a slight increase in IFN-α at 2 DPI, but there was no statistically significant change in serum IFN-α at any time-point for this group.

Both LIV and TBEV infection in sheep elicit a neutralising and cross-neutralising antibody response
A neutralising antibody response was demonstrated in both homologous infection groups, in comparison to the uninfected control animals which were all negative.  Sheep inoculated with LIV developed neutralising antibody titres at 7 DPI which were significantly higher than those observed for the uninfected control sheep, and increased sharply to a group mean reciprocal titre at PRNT50 of over 800 (Figure 2a).  TBEV-inoculated sheep also developed a significant neutralising antibody response at 7 DPI, with titres lower than those observed for LIV-inoculated sheep (Figure 2b). There was a statistically significant difference between titres for LIV-infected and TBEV-infected groups at 9 DPI and 11 DPI (p=0.011 and p=0.004 respectively). Heterologous in vitro neutralisation assays demonstrated the presence of cross-neutralising antibodies in both LIV- and TBEV-infected sheep at lower, but significant, titres (Figures 2a and 2b), with a significant difference between titres for LIV-infected and TBEV-infected groups at 9 DPI and 11 DPI (p=0.007 and p=0.003 respectively).
The heterologous infection groups demonstrated similar neutralising antibody profiles, with the detection of antibodies from 7 DPI, albeit at lower titres due to the lower dose of primary inoculating virus (figures 2c and 2d).  A lower primary dose of LIV induced significant levels of both neutralising and cross-neutralising antibodies, although the secondary inoculation with the higher dose of TBEV at 11 DPI had no effect (figure 2c).  In comparison, although a primary lower dose of TBEV did not produce significant levels of neutralising antibodies, a secondary inoculation with the higher dose of LIV at 11 DPI appeared to have a boosting effect on neutralising antibody titre (figure 2d). 

Detection of LIV in the CNS is associated with the up-regulation of cytokine and chemokine transcripts and severe pathological changes
	LIV was detected in CNS tissues at post-mortem from 3/5 animals within the LIV-infected group.  The severity of clinical signs in these animals was generally associated with increased viral load in the brain (Table 2).  Following analysis of post-mortem tissues from the most severely affected animal (sheep 91367), virus was detected at several points within the CNS, from the cervical spinal cord through to the cortex, and progressing from rostral to caudal regions of the neuraxis there appeared to be a gradual increase in the viral titres detected (Table 2). Virus detected in the brains from sheep 91362 and 91375, demonstrated a more caudal bias. 
	To assess the innate response to neurovirulence of tick-borne viruses, a number of transcripts representative of pro-inflammatory cytokines (IL-1b and IFN-γ), interferon-induced antiviral proteins (Mx1) and chemokines (CXCL10) were investigated. Each transcript has been shown to be up-regulated in brain tissue during virus-induced encephalitis in murine models of infection (Johnson et al., 2008; Palus et al., 2013).  Levels of IL-1b, Mx1, INF-γ and CXCL10 transcript were all elevated in the LIV-infected group in both the pons and medulla regions of the brain, and considerably increased compared to uninfected controls and the TBEV-infected group (Figure 3a). Transcriptional up-regulation was also associated with the detection of virus and viral RNA at post-mortem (Table 2). 
In addition to transcript analysis, evidence of pathological changes and lymphocyte infiltration were examined in all five sheep infected with LIV, and two TBEV-infected sheep, along with two uninfected control sheep for comparison.  No pathological changes were observed in tissues from TBEV-infected and control sheep.  However, tissues taken from 4/5 LIV-infected sheep exhibited pathological findings consistent with viral encephalitis, including leptomeningitis, non-suppurative encephalitis, neuronal degeneration and neuronophagia. Pathological observations within the more rostral regions of the brain (hippocampus, thalamus and occipital and frontal cortex) were not necessarily accompanied by the presence of virus (Table 2). Only the most severely affected sheep (91367) had viable virus recovered from the cortex, although pathology was evident in the cortex of other animals tested.  Generally, where viral RNA could be detected by PCR, virus could also be isolated, although this was not always the case (Table 2).  Investigation of the spinal cord revealed evidence of leptomeningitis and non-suppurative poliomyelitis, with abundant perivascular cuffing of mononuclear cells.  Mild non-suppurative ganglioneuritis was also observed in the dorsal root ganglion (DRG), where inflammation of spinal cord ganglia was associated with infiltration of mononuclear cells (macrophages and lymphocytes) (Table 2).  One exception was sheep 91377, which had no evidence of pathological changes in the CNS; a surprising observation considering that clinical signs included spontaneous nibbling and ataxia.  A further anomaly was observed with sheep 91389, which exhibited pathological changes in the CNS, despite the absence of detectable virus or viral RNA.  This animal had exhibited clinical signs including nibbling, head shaking and ataxia, and was not euthanised until 16 DPI.  The evidence of pathology without detection of virus again suggests that this animal had cleared the infection and may have survived had it not been euthanised, although it retained some neurological sequelae such as nibbling.
Anti-CD3 (T-cell marker) and anti-CD79a (B-cell marker) immunohistochemical labelling of cervical spinal cord and medulla sections taken from control uninfected sheep (Figure 3b: i and ii) and corresponding tissues from LIV-infected sheep 91367 (Figure 3b: iii, iv, v,vi) is shown. In control material, there was an absence of T-cell and B-cell labelling, and no evidence of inflammatory infiltration observed.  An absence of labelling was also observed in tissues from TBEV-infected sheep (not shown). Tissues from LIV-infected sheep 91367, which exhibited severe clinical signs of encephalitis, were positive for CD3-immunolabelled cells, located primarily in the leptomeningeal and perivascular lymphohistiocytic infiltrate (Figure 3b: iii and iv).  CD3 labelling was also evident, to a lesser extent, in the CNS parenchyma, and occasionally in areas of diffuse and focal gliosis and glial nodules.  In LIV-infected sheep with less severe encephalitic signs, there were no inflammatory changes in the CNS, although occasional CD3-labelled cells were observed distributed randomly throughout the parenchyma.  B-cell distribution was similar to that observed for T-cells, but there were fewer cells, both in the leptomeninges, perivascular cuffs, and white and grey matter (Figure 3b: v and vi).  

Discussion
	There are a number of potential reasons for the variation in clinical outcome to LIV and TBEV infection in sheep, including differences in host cell receptor recognition, limited replication and egress of TBEV from sheep cells, or differences in immune response.  LIV infection of sheep induced pyrexia, which was associated with transient viraemia in some animals, and reflected a systemic response to virus dissemination.  The cessation of viraemia coincided with development of a neutralising antibody response. No clinical signs were observed following TBEV infection, although a neutralising antibody response was established. Therefore, TBEV either failed to establish a productive infection and disseminate, or was controlled by cell-mediated immune responses. A robust neutralising antibody response is essential for protection against flaviviruses, playing a crucial early role in defence against disseminated infection (Diamond et al., 2003).  Although infection with both LIV and TBEV elicited a neutralizing antibody response in sheep, the response against LIV infection was significantly greater than that induced by TBEV infection, reflecting the ability of LIV to establish a disseminated infection in the majority of sheep, which stimulated the adaptive response. The lower antibody titre induced by TBEV infection was likely a reflection of the low viral load within TBEV-infected sheep. Vertebrate hosts naturally infected with TBEV are known to play an important role in non-viraemic TBEV transmission via co-feeding ticks, where virus is transmitted between infected and uninfected ticks feeding closely on a mammalian host with no detectable viraemia (Labuda et al., 1993).  Therefore, it is unclear whether an increased or more localized infected tick burden would induce a more extensive viraemia.  However, it is possible that the lack of detectable viraemia in this study may be related to the lower virulence of the Neudorfl TBEV strain used, since the detection of TBEV in unpasteurized sheep milk (Cisak et al., 2010) suggests that viraemia may occasionally occur in some sheep following infection with a more virulent TBEV strain, although this viraemia would be short-lived and of low titre (Grešíková, 1958).    
Cross-reactivity between flaviviruses has been well-documented, resulting in both cross-protection (O’Reilly et al., 1965) and cross-neutralisation (Calisher et al., 1989; Mansfield et al., 2011).  Following infection with either LIV or TBEV, neutralising antibodies raised in sheep were also able to cross-neutralise, suggesting that neutralising epitopes on the envelope glycoprotein are similar or identical for both viruses.  This cross-reactivity led to some degree of cross-protection, where a primary low dose of TBEV caused a delay in onset of clinical signs induced by secondary challenge with a high dose of LIV, leading to a delay in development of pyrexia. Additionally, the primary inoculation with a low dose of TBEV appeared to prime the immune system, leading to a massive boost of TBEV-specific antibodies around 7 days after secondary inoculation with high-dose LIV.  
Although the humoral response to flavivirus infection in sheep has been well-reported, the innate immune response has yet to be characterised.  However, along with a humoral response, inoculation of sheep with LIV was shown to initiate a strong innate immune response, with the elevation of serum IFN-α coinciding with the viraemic phase in LIV-infected sheep.  Additionally, the up-regulation of transcripts for cytokines and chemokines IL-1b, Mx1, IFN-γ and CXCL10 was detected in the brain at post-mortem, and associated with detection of virus and viral RNA.  These transcripts have previously been shown to be up-regulated in the CNS following infection with other encephalitic viruses including rabies virus (RABV) and West Nile virus (WNV) (Johnson et al., 2008; Kumar et al., 2010; Michlmayr et al., 2014).  In particular, IFN-γ plays a role in the transition from innate to adaptive immune response, and is secreted by activated T-cells (Boehm et al., 1997). Infection with LIV induced demonstrable infiltration of the brain parenchyma with CD3+ T-cells that may be the source for an increase in IFN-γ transcripts. Elevated levels of the chemokines CXCL10 and CXCL11 have also been detected in CSF during human TBEV infection (Lepej et al., 2007) so the up-regulated CXCL10 transcript levels in the brain of LIV-infected sheep is a consistent observation for flavivirus infection of mammals.  However, whilst a vigorous immune response is essential for controlling flavivirus infection in the CNS, it has also been implicated in contributing to neuropathology.  Although CXCL10 has been associated with control of WNV infection through T-cell recruitment (Klein et al., 2005), it has also been implicated in the neuropathogenesis of WNV infection (Van Marle et al., 2007), whilst the pro-inflammatory cytokine response following WNV infection has been shown to increase neuronal death (Kumar et al., 2010). Additionally, T-cells have been linked to a fatal outcome in human TBEV (Ruzek et al., 2009).  The detection of LIV in CNS tissues following infection in sheep was associated with the detection of T-cells, which were more numerous than B-cells in the brain and spinal cord. Therefore, the infiltration of immune cells into the CNS, orchestrated via the innate immune response and directed by chemokines, may contribute to the fatal outcome observed following infection with LIV.  Under rare circumstances, ovines can become infected with TBEV (Bago et al., 2002).  However, in general, the absence of clinical disease caused by TBEV infection in sheep may be due to poor replication of virus within sheep cells, with little or no dissemination.  A detectable type-1 IFN response is not initiated, and the humoral immune response is sufficient to control infection and prevent neuroinvasion and immunopathology. 
Further studies will enhance the understanding of the mammalian immune response to flavivirus infection, potentially advancing the development of effective disease prevention strategies for both human and veterinary medicine.  
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Figure legends

Figure 1: Experimental LIV infection in sheep induces pyrexia and production of type I IFN in the periphery, whilst TBEV infection does not. (a) Comparison of mean rectal temperatures for sheep following a single inoculation with LIV and TBEV. (b) Comparison of mean rectal temperatures for sheep infected with a primary lower dose of LIV and TBEV, followed by a secondary inoculation with heterologous virus at 11 DPI. (c) Comparison of serum type I interferon for sheep following a single inoculation with LIV and TBEV. Statistically significant change in comparison to the uninfected control represented by * (p<0.05) or *** (p<0.001). † represents one animal only.

Figure 2: Both LIV and TBEV infection in sheep induce neutralising antibodies.  Comparison of serum neutralising and cross-neutralising antibodies (mean reciprocal PRNT50 titre) for sheep following inoculation with LIV and TBEV (a) Single inoculation with 5 x 106 PFU of LIV. (b) Single inoculation with 5 x 106 PFU of TBEV. (c) Primary inoculation with 5 x 103 PFU of LIV, followed by a secondary inoculation with 5 x 106 PFU of TBEV at 11 DPI. (d) Primary inoculation with 5 x 103 PFU of TBEV, followed by a secondary inoculation with 5 x 106 PFU of LIV at 11 DPI.  LIV-specific antibodies represented by black bars, and TBEV-specific antibodies by grey bars. Statistically significant change in comparison to the uninfected control represented by * (p<0.05) or ** (p<0.01). # represents one animal only. 

Figure 3: LIV infection in sheep induces transcriptional up-regulation of cytokines and chemokines in the CNS, which is coincident with infiltration of T- and B-cells into the CNS.  (a): Detection of cytokine/chemokine transcripts in post-mortem brain from LIV-, TBEV- and uninfected sheep; IL-1b, Mx1, IFN-γ and CXCL10.  Light grey bars represent the pons region, and dark grey bars represent the medulla region.  Data were log-transformed prior to analysis, and statistically significant changes represented by * (p<0.05). Detransformed mean transcript fold-changes for uninfected, LIV- and TBEV-infected respectively were 1.0, 26.5 and 5.5 for IL-1b (pons); 1.0, 5.5 and 1.3 for IL-1b (medulla); 0.9, 266.4 and 1.9 for Mx1 (pons); 0.8, 133.8 and 1.7 for Mx1 (medulla); 0.9, 22.5 and 2.3 for IFN-γ (pons); 0.9, 18.3 and 3.5 for IFN-γ (medulla); 0.8, 52.4 and 1.5 for CXCL10 (pons); 1.0, 71.6 and 3.4 for CXCL10 (medulla).
 (b): Immunohistochemical labelling of CD3 T-lymphocytes and CD79a B cells in the cervical spinal cord and medulla oblongata sections taken from a sheep inoculated subcutaneously with a high dose of LIV and exhibiting severe clinical signs.  (i) Uninfected sheep cervical spinal cord - absence of CD3 T-lymphocyte labelling labelling and lack of inflammatory infiltration (arrows: blood vessels).  Original magnification 200X (ii) Uninfected sheep medulla oblongata - absence of CD3 T-lymphocyte labelling and lack of inflammatory infiltration (arrows: blood vessels). Original magnification 200X (iii) CD3 T-lymphocytes in the cervical spinal cord following LIV infection, associated with perivascular cuffs (arrow) and infiltrating the adjacent parenchyma (arrowhead). Original magnification 400X (iv) CD3 T-lymphocytes in the medulla oblongata following LIV infection, associated with perivascular cuffs (arrow). Original magnification 400X (v) CD79a B-cells in the cervical spinal cord following LIV infection, associated with perivascular cuffs (arrow head). Original magnification 400X (vi) CD79a B-cells in the medulla oblongata following LIV infection, associated with perivascular cuffs (arrow head). Original magnification 400X.


Table 1: Clinical outcome following inoculation of sheep with LIV or TBEV. * euthanasia on clinical grounds. Clinical signs classified as detailed in Materials and Methods.

Inoculation dose (PFU) 	Sheep ID	Clinical signs	Euthanasia (DPI)	Viremia (PFU/ml)
Primary(0 DPI)	Secondary(11 DPI)		Onset (DPI)	Severity		
LIV(5 x105)	n/a	91367	3	+++	8*	Negative
		91362	3	++	8*	8.8 x 102
		91375	3	++	14*	8.0 x 103
		91377	3	++	8*	2.4 x 102
		91389	3	++	16*	Negative
TBEV(5 x 105)	n/a	91372	-	-	22	Negative
		91371	-	-	22	Negative
		91357	-	-	22	Negative
		91392	-	-	22	Negative
		91394	-	-	22	Negative
LIV (5 x 103) 	TBEV (5 x 105)	91356	3	-	23	2.0 x 102 
		91365	3	+	23	Negative
		91390	4	++	23	Negative
		91391	-	-	23	Negative
		91386	16	+	23	Negative
TBEV (5 x 103) 	LIV (5 x 105)	91378	-	-	21	Negative
		91364	19	+	21	Negative
		91396	18	+++	19*	Negative
		91383	18	+	21	Negative
		91183	18	+	21	Negative
Uninfected	n/a	91347	-	-	18	Negative
		91350	-	-	18	Negative
		91353	-	-	18	Negative





Table 2: Quantification of virus in CNS tissues from single-dose LIV-infected sheep (PFU/mg tissue) and association with viral RNA and pathological changes.  Individual animals displayed in decreasing severity of disease (91367>91362>91375>91377>91389); clinical signs classified in Materials and Methods.

Sheep ID		Lumbar spinal cord	Cervical spinal cord	Medulla	Pons	Cerebellum	Cortex
91367	Viral RNA	-	+	+	+	+	+
	Virus (PFU/mg)	-	2583.3	467.4	1.25	16.7	0.37
	Pathology	-	+	+	+	+	+
91362	Viral RNA	-	+	+	+	+	-
	Virus (PFU/mg)	-	0.16	34.5	23.5	38.3	-
	Pathology	-	+	+	+	+	+
91375	Viral RNA	+	+	+	+	+	-
	Virus (PFU/mg)	0.75	-	0.38	0.63	-	-
	Pathology	+	+	+	+	+	+
91377	Viral RNA	-	-	-	-	-	-
	Virus (PFU/mg)	-	-	-	-	-	-
	Pathology	-	-	-	-	-	-
91389	Viral RNA	-	-	-	-	-	-
	Virus (PFU/mg)	-	-	-	-	-	-
	Pathology	+	+	+	+	+	+
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